Anesthetic management in patients undergoing hyperthermic chemotherapy

Current Opinion in Anaesthesiology

Volumn 25, Issue 3, 2012, Pages 348-355

  Raspe, Christoph ^a   Piso, Pomipilu ^b   Wiesenack, Christoph ^c   Bucher, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Oncology and Hematology   (Germany)

^c St Marienhospital ^*  (Germany)

Author keywords

anesthetic and intensive care management; hyperthermic intraperitoneal chemotherapy

Indexed keywords

ANALGESIC AGENT; BLOOD CLOTTING FACTOR 13; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; FRESH FROZEN PLASMA; HUMAN ALBUMIN; IRINOTECAN; LACTIC ACID; MITOMYCIN C; OPIATE; OXALIPLATIN;

ABDOMINAL PRESSURE; ANESTHESIA; ANESTHESIST; APPENDIX CANCER; ASCITES; BLOOD PRESSURE; BLOOD VOLUME; BONE MARROW TOXICITY; CANCER PROGNOSIS; CARCINOMATOUS PERITONITIS; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOTHERAPY; COLON CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG TOLERANCE; DYSESTHESIA; ELECTROLYTE DISTURBANCE; GLYCOCALYX; HEART ARRHYTHMIA; HEART OUTPUT; HEMODYNAMICS; HEMOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERMETABOLISM; HYPERTHERMIA; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; HYPERVOLEMIA; HYPONATREMIA; HYPOTHERMIA; HYPOVOLEMIA; INTENSIVE CARE; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LETHALITY; LUNG TOXICITY; MAGNESIUM BLOOD LEVEL; MESOTHELIOMA; METABOLIC ACIDOSIS; METABOLIC RATE; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; OVARY CANCER; PATHOPHYSIOLOGY; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHYSICIAN; POSITIVE END EXPIRATORY PRESSURE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN DEPLETION; QT PROLONGATION; QUALITY OF LIFE; RECTUM CANCER; REVIEW; SPINAL HEMATOMA; STOMACH CANCER; SURGICAL TECHNIQUE; THERMODILUTION; THORAX EPIDURAL ANESTHESIA; THROMBOCYTE; THROMBOELASTOGRAPHY;

ANESTHESIA; BLOOD COAGULATION; BODY TEMPERATURE; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; FLUID THERAPY; HEMODYNAMICS; HUMANS; HYPERTHERMIA, INDUCED; PAIN MANAGEMENT; PERIOPERATIVE CARE; PERITONEAL NEOPLASMS; POSTOPERATIVE CARE;

EID: 84861099055     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32835347b2     Document Type: Review

References (67)

1. Raue W, Tsilimparis N, Langelotz C, et al. Initial results after implementation of a multimodal treatment for peritoneal malignancies. Acta Chir Belg 2011;111:68-72. Describes that HIPEC leads to promising results for patients suffering from peritoneal carcinomatosis; however, this treatment concept is afflicted with a relevant risk of postoperative complications.
2. Königsrainer I, Beckert S, Lehmann T, et al. Peritoneal carcinomatosis. Chirurg 2011;82:375-380. Highlights that not only technical surgical aspects but also intraoperative management, intensive care therapy, pain therapy, management of complications, and physiotherapy are relevant factors for successful processing HIPEC.
3. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681-685.
4. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multiinstitutional experience. J Clin Oncol 2009;27:6237-6242.
5. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426-2432.
6. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63-68. Summarizes that HIPEC is now considered the gold standard in the French guidelines.
7. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 2007;14:128-133.
8. Jacquet P, Averbach A, Stephens AD, et al. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 1998;55:130-138.
9. Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 2004;15:1558-1565.
10. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007;10:2702-2713.
11. Tang L, Mei LJ, Yang XJ, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study. J Transl Med 2011;9:53. Concludes that the combination of chemotherapeutics during HIPEC period significantly prolongs the survival with acceptable safety in comparison to single use of chemotherapeutics.
12. Ausmus PL, Wilke AV, Frazier DL. Effects of hyperthermia on blood flow and cis-diamminedichloroplatinum (II) pharmacokinetics in murine mammary adenocarcinomas. Cancer Res 1992;52:4965-4968.
13. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235-244.
14. Steller MA, Egorin MJ, Trimble EL, Bartlett DL, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999;43:106-114.
15. González-Bayón L, González-Moreno S, Ortega-Pérez G. Safety considerations for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion. Eur J Surg Oncol 2006;32:619-624.
16. Schmid K, Boettcher MI, Pelz JO, et al. Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C. Eur J Surg Oncol 2006;32:1222-1225.
17. Tsiftsis D, de Bree E, Romanos J, et al. Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. Arch Surg 1999;134:545-549; discussion 550.
18. Shime N, Lee M, Hatanaka T. Cardiovascular changes during continuous hyperthermic peritoneal perfusion. Anesth Analg 1994;78:938-942.
19. Kanakoudis F, Petrou A, Michaloudis D, et al. Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, oxygen consumption and delivery. Anaesthesia 1996;51:1033-1036.
20. Izzo L, Pierannunzi F, Vari A, et al. Anaesthesiologic problems about hyperthermic intraoperative intraperitoneal chemotherapy. G Chir 2004;25:361-364.
21. Esquivel J, Angulo F, Bland RK, et al. Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open 'coliseum technique'. Ann Surg Oncol 2000;7:296-300.
22. Michelson AD, MacGregor H, Barnard MR, et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994;71:633-640.
23. Morris DL, Chambers HF, Morris MG, et al. Hemodynamic characteristics of patients with hypothermia due to occult infection and other causes. Ann Intern Med 1985;102:153-157.
24. Seekamp A, van Griensven M, Hildebrandt F, et al. Adenosine-triphosphate in trauma-related and elective hypothermia. J Trauma 1999;47:673-683.
25. Cafiero T, Di Iorio C, Di Minno RM, et al. Noninvasive cardiac monitoring by aortic blood flow determination in patients undergoing hyperthermic intraperitoneal intraoperative chemotherapy. Minerva Anestesiol 2006;72:207-215.
26. Schmidt C, Creutzenberg M, Piso P, et al. Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia 2008;63:389-395.
27. Meininger D, Byhahn C, Mierdl S, et al. Positive end-expiratory pressure improves arterial oxygenation during prolonged pneumoperitoneum. Acta Anaesthesiol Scand 2005;49:778-783.
28. Fleischmann E, Kugener A, Kabon B, et al. Laparoscopic surgery impairs tissue oxygen tension more than open surgery. Br J Surg 2007;94:362-368.
29. Meininger D, Zwissler B, Byhahn C, et al. Impact of overweight and pneumoperitoneum on hemodynamics and oxygenation during prolonged laparoscopic surgery. World J Surg 2006;30:520-526.
30. Kashtan J, Green JF, Parsons EQ, et al. Hemodynamic effect of increased abdominal pressure. J Surg Res 1981;30:249-255.
31. Dexter SP, Vucevic M, Gibson J, et al. Hemodynamic consequences of highand low-pressure capnoperitoneum during laparoscopic cholecystectomy. Surg Endosc 1999;13:376-381.
32. Biancofiore G, Amorose G, Lugli D, et al. Perioperative anesthetic management for laparoscopic kidney donation. Transplant Proc 2004;36:464-466.
33. Bickel A, Arzomanov T, Ivry S, et al. Reversal of adverse hemodynamic effects of pneumoperitoneum by pressure equilibration. Arch Surg 2004;139:1320-1325.
34. Mertens zur Borg IR, Lim A, Verbrugge SJ, et al. Effect of intraabdominal pressure elevation and positioning on hemodynamic responses during carbon dioxide pneumoperitoneum for laparoscopic donor nephrectomy: a prospective controlled clinical study. Surg Endosc 2004;18:919-923.
35. Nguyen NT, Wolfe BM. The physiologic effects of pneumoperitoneum in the morbidly obese. Ann Surg 2005;241:219-226.
36. Perez J, Taura P, Rueda J, et al. Role of dopamine in renal dysfunction during laparoscopic surgery. Surg Endosc 2002;16:1297-1301.
37. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29:1526-1531.
38. Karthik S, Lisbon A. Low-dose dopamine in the intensive care unit. Semin Dialysis 2006;19:465-471.
39. Chappell D, Jacob M, Hofmann-Kiefer K, et al. A rational approach to perioperative fluid management. Anesthesiology 2008;109:723-740.
40. Vorgias G, Iavazzo C, Mavromatis J, et al. Determination of the necessary total protein substitution requirements in patients with advanced stage ovarian cancer and ascites, undergoing debulking surgery. Correlation with plasma proteins. Ann Surg Oncol 2007;14:1919-1923.
41. Jacob M, Rehm M, Orth V, et al. Exact measurement of the volume effect of 6% hydoxyethyl starch 130/0.4 (Voluven) during acute preoperative normovolemic hemodilution. Anaesthesist 2003;52:896-904.
42. Lowell JA, Schifferdecker C, Driscoll DF, et al. Postoperative fluid overload: not a benign problem. Crit Care Med 1990;18:728-733.
43. Payen D, de Pont AC, Sakr Y, et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008;12:R74.
44. Ertmer C, Rehberg S, van Aken H, et al. Physiologische Grundlagen der perioperativen Flüssigkeitstherapie. Intensivmed up2date 2009;4:9-20.
45. Raue W, Tsilimparis N, Bloch A, et al. Volume therapy and cardiocircular function during hyperthermic intraperitoneal chemotherapy. Eur Surg Res 2009;43:365-372.
46. Rehm M, Zahler S, Lötsch M, et al. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology 2004;100:1211-1223.
47. Bundgaard-Nielsen M, Holte K, Secher N, et al. Monitoring of perioperative fluid administration by individual goal-directed therapy. Acta Anaesthesiol Scand 2007;51:331-340.
48. De Somer F, Ceelen W, Delanghe J, et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 2008;28:61-66.
49. Raft J, Parisot M, Marchal F, et al. Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolytes changes and on the acid-base balance. Ann Fr Anesth Reanim 2010;29:676-681. Pinpoints that hyperglycemia and hyponatremia might result from HIPEC and that glycemic control should be performed in order to avoid the other metabolic disturbances.
50. Sakka SG, Ruhl CC, Pfeiffer UJ, et al. Assessment of cardiac preload and extravascular lung water by single transpulmonary thermodilution. Intensive Care Med 2000;26:180-187.
51. Hofer CK, Senn A, Weibel L, et al. Assessment of stroke volume variation for prediction of fluid responsiveness using the modified FloTrac and PiCCOplus system. Crit Care 2008;12:R82.
52. Miao N, Pingpank JF, Alexander HR, et al. Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations. Ann Surg Oncol 2009;16:334-344.
53. Thix CA, Königsrainer I, Kind R, et al. Ventricular tachycardia during hyperthermic intraperitoneal chemotherapy. Anaesthesia 2009;64:1134-1136.
54. Hansen E, Knuechel R, Altmeppen J, Taeger K. Blood irradiation for intraoperative autotransfusion in cancer surgery: demonstration of efficient elimination of contaminating tumor cells. Transfusion 1999;39:608-615.
55. Hansen E, Bechmann V, Altmeppen J. Intraoperative blood salvage with irradiation of blood in cancer surgery: answers to current queries. Anasthesiol Intensivmed Notfallmed Schmerzther 2002;37:740-744.
56. Arakelian E, Gunningberg L, Larsson J, et al. Factors influencing early postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2011;37:897-903. Concludes that use of CPAP has an impact on postoperative recovery in HIPEC patients and should be discussed with the patients preoperatively and taken into consideration in designing an individualized patient care plan, in order to attain a more efficient recovery.
57. Cooksley TJ, Haji-Michael P. Postoperative critical care management of patients undergoing cytoreductive surgery and Heated Intraperitoneal Chemotherapy (HIPEC). World J Surg Oncol 2011;9:169. Summarizes consequently all important considerations concerning perioperative care of patients undergoing HIPEC.
58. Zielmann S, Grote R. The effects of long-term sedation on intestinal function. Anaesthesist 1995;44(Suppl 3):S549-S558.
59. Blumenthal S, Min K, Nadig M, et al. Double epidural catheter with ropivacaine versus intravenous morphine: a comparison for postoperative analgesia after scoliosis correction surgery. Anesthesiology 2005;102:175-180.
60. De la Chapelle A, Pérus O, Soubielle J, et al. High potential for epidural analgesia neuraxial block-associated hypotension in conjunction with heated intraoperative intraperitoneal chemotherapy. Reg Anesth Pain Med 2005;30:313-314.
61. Desgranges FP, Steghens A, Rosay H, et al. Epidural analgesia for surgical treatment of peritoneal carcinomatosis: A risky technique? Ann Fr Anesth Reanim 2011;31:53-59. Concluding pros and cons for supplementary epidural anesthesia during HIPEC.
62. Desgranges FP, Steghens A, Mithieux F, et al. Potential risks of thoracic epidural analgesia in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2010;101:442. Concluding pros and cons for supplementary epidural anesthesia during HIPEC.
63. Wulf H. Epidural anaesthesia and spinal haematoma. Can J Anaesth 1996;43:1260-1271.
64. Schmidt C, Moritz S, Rath S, et al. Perioperative management of patients with cytoreductive surgery for peritoneal carcinomatosis. J Surg Oncol 2009;100:297-301.
65. Horlocker T, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003;28:172-197.
66. Kessler P. Update rückenmarksnahe Anästhesie und Analgesie: weniger Nutzen, mehr Gefahr? Anästhesiologie Intensivmedizin 2011;11:846-860. Highlights that complications rates of epidural anesthesia might be higher than considered through out the last years and therefore, indication for paravertebral anesthesia should be made with caution.
67. Synder G, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010;105:106-115. States that in retrospective analyses outcome benefit for paravertebral analgesia during cancer surgery occurred.